# Baxter International Inc. account plan

> Baxter International is a Deerfield, Illinois medtech group with FY2025 net sales of $11.24 billion and about 37,500 employees.

## At a glance

Baxter International Inc. sells sterile IV solutions, infusion systems, parenteral nutrition, surgical hemostats and sealants, specialty injectables, inhaled anesthetics, smart beds, patient monitoring and respiratory devices. Its customers are hospitals, nursing homes, ambulatory surgery centers, doctors' offices and patients at home, reached through a direct sales force, distributors and U.S. group purchasing organizations. It manufactures in over 20 countries and sells in over 100, with approximately 37,500 employees. FY2025 net sales were $11.24 billion (+6% reported, +3% operational), with a net loss attributable to Baxter of $(957) million after $2.07 billion of special items. The Kidney Care business (now Vantive) was sold to Carlyle on January 31, 2025.

## Business units

- **Medical Products & Therapies (MPT)** ($5,299 million of FY2025 sales, about 47%): Sterile IV solutions, infusion systems, administration sets, parenteral nutrition and surgical hemostats and sealants; since Q2 2026 it also holds specialty injectables, inhaled anesthesia and drug compounding inside the Infusion Therapies & Platforms division. Q3 2026 sales were about $2.1 billion, +6%, with Advanced Surgery at $342 million, +12%. Maria Cecilia Soriano is Group President, Infusion Therapies & Technologies & Pharmaceuticals.
- **Healthcare Systems & Technologies (HST)** ($3,071 million of FY2025 sales, about 27%): Smart bed systems, connected monitoring, diagnostics, respiratory health devices and surgical equipment, split into Care & Connectivity Solutions and Front Line Care (mostly the former Welch Allyn). Q3 2026 sales were $806 million, +4%, with an adjusted operating margin of 17.2%. Led by Reazur Rasul, Executive Vice President and Group President.
- **Pharmaceuticals (reported until Q1 2026)** ($2,493 million of FY2025 sales, about 22%): Specialty injectable pharmaceuticals, inhaled anesthetics and drug compounding services, with plants in Guayama (Puerto Rico), Round Lake (Illinois) and Ahmedabad (India). In FY2025 Drug Compounding grew +10% reported while Injectables and Anesthesia fell 2%. From Q2 2026 it is reported inside MPT's Infusion Therapies & Platforms division.
- **Other (Vantive MSA)** ($381 million of FY2025 sales, about 3%): Mainly sales to Vantive under the Kidney Care Manufacturing and Supply Agreement, plus contract manufacturing. Q3 2026 Other sales were $68 million vs $85 million.

## Strategic priorities

- **Stabilize the business**: Under CEO Andrew Hider the first phase is stabilizing operations: in Care & Connectivity Solutions an on-time shipment metric improved 8% year over year, and an Advanced Surgery quality measure improved by nearly 20%.
- **Deleverage to about 3x by end-2026**: Baxter targets a net leverage of approximately 3.0x by the end of 2026 while keeping an investment grade rating; the dividend was cut to $0.01 per share and no buybacks are made during deleveraging.
- **Continuous improvement through Baxter GPS**: The Baxter Growth and Performance system, launched in October 2025, delivered more than 700 initiatives in 2026, with more than 200 in flight and about 350 planned, alongside automation, digitization and the exploration of AI.
- **Decentralized, simpler organization**: Baxter has moved to independent P&Ls and implemented a new two-segment operating model in Q2 2026, removing managerial layers and keeping some shared corporate costs unallocated.
- **Innovation in connected care**: Priorities include connected care offerings such as Connex 360 monitoring, the Dynamo Series Smart Stretcher, and the IQX platform linking the Spectrum LVP and Novum syringe.
- **Portfolio buckets and tuck-in M&A**: The portfolio is split into invest-and-grow (ambulatory cardiac monitoring with Bardy, Advanced Surgery), sustain (IV solutions) and fix; future moves are expected to be more pruning, and tuck-in acquisitions are judged on strategic rationale, market attractiveness, integration and financial return.

## Latest results

In Q3 2026 net sales were $2,976 million vs $2,835 million, +5% reported and +5% organic, with U.S. sales of $1,595 million and International $1,381 million. Net income attributable to Baxter was $294 million, or $0.57 per diluted share, against $(46) million a year earlier, helped by a $253 million gain on early debt extinguishment; adjusted EPS was $0.58. Free cash flow was $448 million in the quarter and $705 million year-to-date. Over nine months net sales were $8,637 million, +4% reported. Baxter raised its FY2026 outlook to reported sales growth of 4% to 5%, organic growth of 3% to 4% and adjusted EPS of $2.05 to $2.15.

## Investments and deals

- **Kidney Care divestment**: The Kidney Care business was sold to Carlyle on January 31, 2025 for an aggregate $3.80 billion; about $3.2 billion of after-tax proceeds were used to repay debt.
- **Debt reduction and tender offer**: Total debt repayments in 2025 were $5.49 billion; in September 2026 a $600 million cash tender offer retired $864 million of debt, according to the earnings release.
- **Capital expenditure**: Capital expenditures were $513 million in FY2025 and $363 million over the first nine months of 2026, focused on production efficiency, quality systems and capacity.
- **Restructuring and cephalosporin exit**: 2026 restructuring targets the post-Kidney Care cost structure ($79 million of employee termination costs over nine months) and the end of cephalosporin production at the Round Lake, Illinois plant ($39 million).

## Challenges and risks

- **Novum LVP recalls**: Class I recalls from 2025 led to about $105 million of charges in 2025, and the U.S./Canada ship and install hold continues with no meaningful Novum LVP sales expected meanwhile.
- **FDA Warning Letter at Round Lake**: An FDA inspection in March-April 2026 led to an OAI classification and a Warning Letter in September 2026; Baxter is implementing corrective actions.
- **Margin pressure and Front Line Care impairments**: FY2025 gross margin fell to 30.1% from 37.5%, and Front Line Care took a $485 million goodwill impairment in Q4 2025 plus a $290 million Welch Allyn trade name impairment.
- **Tariffs and inflation**: Section 122 duties and Section 301 tariffs are still expected to weigh on results, and the CFO expects higher inflation led by salaries, then electronics and materials, in 2027.
- **Kidney Care dis-synergies**: Vantive TSA services end by the end of January 2027, leaving stranded costs, and the risk factors name dis-synergies from the reduced size of the company.

## What leadership says

> "We delivered a strong third quarter, with growth across all segments and divisions globally" — Andrew Hider, President and CEO, Baxter reports third-quarter 2026 results, earnings release, October 29, 2026

> "further evidence that our turnaround is gaining traction" — Andrew Hider, President and CEO, Baxter Q3 2026 earnings call, October 29, 2026

> "If you can measure it, you can manage it. If you can manage it, you can improve it." — Andrew Hider, President and CEO, Wells Fargo 21st Annual Healthcare Conference fireside chat, September 9, 2026

> "I have been pleased with the progress, but we are not yet happy with the results yet" — Andrew Hider, President and CEO, Wells Fargo 21st Annual Healthcare Conference fireside chat, September 9, 2026


## Where a supplier can help

- **IT and finance cost reduction**: The CFO named IT (a large number of applications) and finance costs as savings opportunities to offset inflation and Kidney Care dis-synergies; application rationalization and finance automation suppliers fit that challenge.
- **Quality and regulatory remediation**: The Round Lake Warning Letter and the Novum LVP recalls create demand for quality systems, validation and regulatory consulting support tied to the stabilization priority.
- **Manufacturing productivity under Baxter GPS**: With hundreds of continuous improvement initiatives and plant teams using AI, automation, digitization and lean tooling providers can support the continuous improvement priority and the capex focus on production efficiency.
- **Supply chain resilience**: Tariffs, a contract manufacturer's supply problems in injectables and single-source supplier risk make alternative sourcing, supplier quality and tariff mitigation services relevant.
- **Connected care technology partners**: The invest-and-grow push in cardiac monitoring and connected care (Connex 360, IQX) opens room for software, data and component partners that help gather data across the care workflow.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/10456/000162828026007733/bax-20251231.htm)

Annual report · 2026-02-12

- Baxter International is a Deerfield, Illinois medtech group (incorporated 1931) selling sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, generic injectables, surgical hemostats and sealants, smart beds, patient monitoring and respiratory devices to hospitals, nursing homes, ambulatory surgery centers, doctors' offices and home patients; ~37,500 employees, products sold in over 100 countries.
- FY2025 net sales $11.24 billion, +6% reported and +3% operational; U.S. $6,122 million, emerging markets $1,394 million, rest of world $3,728 million.
- Three reportable segments in FY2025: Medical Products & Therapies ($5,299 million), Healthcare Systems & Technologies ($3,071 million), Pharmaceuticals ($2,493 million); segment operating income $970 million, $441 million and $222 million.
- Net loss attributable to stockholders $(957) million, or $(1.87) per diluted share, after $2.09 billion of special items, including a $485 million goodwill impairment on Front Line Care and $290 million of indefinite-lived asset impairments; GAAP gross margin 30.1% vs 37.5%.
- Kidney Care (now Vantive) sold to Carlyle on January 31, 2025 for $3.80 billion; $3.81 billion of legacy debt repaid in 2025; net leverage target of approximately 3.0x by end-2026; quarterly dividend cut to $0.01 per share in November 2025, no share repurchases during deleveraging.
- Andrew Hider (ex-ATS Corporation, Danaher) became President and CEO in 2025; launched the Baxter Growth and Performance system in October 2025 and is removing managerial layers.
- Operational headwinds: Novum IQ large volume pump under Class I recalls with a U.S./Canada ship and install hold (about $105 million of charges in 2025); lower U.S. IV solutions demand after Hurricane Helene-driven fluid conservation; tariffs and inflation.
- R&D $518 million and capex $513 million in 2025; operating cash flow from continuing operations $951 million; S&P cut to BBB- and Moody's to Baa3 (outlook Stable).

### [Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/10456/000162828026068278/bax-20260930.htm)

Interim report · 2026-10-29

- Q3 2026 net sales $2,976 million, +5% reported; U.S. $1,595 million (+3% reported, +5% organic), International $1,381 million (+7% reported, +6% organic). Nine months: $8,637 million, +4% reported, +3% organic.
- New operating model from Q2 2026: two reportable segments. The former Pharmaceuticals segment now sits in the Infusion Therapies & Platforms division of Medical Products & Therapies; prior periods recast.
- Medical Products & Therapies Q3 sales $2,102 million (+6%): Infusion Therapies & Platforms $1,760 million (+5%), Advanced Surgery $342 million (+12%); segment operating income $439 million.
- Healthcare Systems & Technologies Q3 sales $806 million (+4%): Care & Connectivity Solutions $498 million (+5%), Front Line Care $308 million (+3%); segment operating income $139 million.
- Q3 net income attributable to Baxter $294 million, $0.57 per diluted share, including a $253 million gain on early debt extinguishment.
- Nine-month operating cash flow $1,068 million (vs $355 million); cash $1.98 billion; long-term debt and finance leases about $8.60 billion; no share repurchases ($1.30 billion authorization remaining).
- FDA issued a Warning Letter on the Round Lake, Illinois sterile injectables plant in September 2026; the Novum LVP U.S./Canada ship and install hold continues.
- About $75 million of IEEPA tariff refunds were booked in Q2 2026; Section 122 duties and Section 301 tariffs still weigh on results.

### [Baxter reports third-quarter 2026 results (earnings release)](https://www.sec.gov/Archives/edgar/data/10456/000001045626000004/bax-20260930xex991.htm)

Interim report · 2026-10-29

- Q3 2026 sales $2.98 billion, +5% reported and organic, with growth in all segments and divisions; U.S. about $1.6 billion, International about $1.4 billion.
- GAAP diluted EPS $0.57; adjusted diluted EPS $0.58, down 16% on a higher effective tax rate.
- Free cash flow $448 million in Q3 and $705 million year-to-date.
- Completed a $600 million cash tender offer, retiring $864 million of debt.
- Medical Products & Therapies about $2.1 billion (+6%): Infusion Systems, Drug Compounding and IV Solutions led, Injectables declined; strong Advanced Surgery demand.
- Healthcare Systems & Technologies about $806 million (+4%): Global Surgical Solutions and Patient Support Systems, plus Front Line Care growth.
- FY2026 outlook raised: reported sales growth 4% to 5% (was 3% to 4%), organic 3% to 4% (was 2% to 3%), adjusted EPS $2.05 to $2.15 (was $1.95 to $2.15).
- CEO Andrew Hider: steady progress "stabilizing the business, strengthening the balance sheet and driving continuous improvement".

### [Baxter Q3 2026 earnings call transcript](https://stockanalysis.com/stocks/bax/transcripts/719784-q3-2026/)

Executive talk · Andrew Hider, President and Chief Executive Officer · 2026-10-29

- CEO Andrew Hider says the third quarter is "further evidence that our turnaround is gaining traction": sales about $3 billion, +5% reported and organic, adjusted EPS $0.58; FY2026 organic growth guidance raised to 3%-4% and adjusted EPS to $2.05-$2.15.
- Three priorities: stabilize the business, strengthen the balance sheet, embed continuous improvement (Baxter GPS: more than 700 continuous improvement initiatives year to date, more than 200 in flight, about 350 planned).
- Baxter will stop producing cephalosporin products at Round Lake, Illinois (about $50 million of sales and $30 million of operating income in 2026), partly to address the FDA warning letter; $39 million of restructuring booked.
- Free cash flow $448 million in Q3, $705 million year-to-date; $600 million tender offer retired $854 million of debt; confident of about 3x net leverage by year-end.
- After 3x: internal investment, tuck-in acquisitions (cardiac monitoring, Advanced Surgery named as invest-and-grow areas) and share repurchases.
- New CFO John Rogers (joined October 1, 2026) targets margin mix, a multi-year efficiency pipeline (IT and finance costs benchmark high) and a sharper capital allocation policy; 2027 guidance comes in February.
- 2027 headwinds named: inflation (salaries, electronics, materials), tariffs without the 2026 refund, the end of Vantive TSAs by end of January 2027, product exits; offset by cost savings.
- Segments: MPT adjusted operating margin 20.9%, HST 17.2%; Advanced Surgery +12% helped by a competitor's supply problem; drug compounding +9%; injectables -3%.

### [Wells Fargo 21st Annual Healthcare Conference fireside chat](https://stockanalysis.com/stocks/bax/transcripts/734485-wells-fargo-21st-annual-healthcare-conference/)

Executive talk · Andrew Hider, President and Chief Executive Officer · 2026-09-09

- Andrew Hider, a little over a year as CEO, says he has decentralized Baxter into independent P&Ls and launched GPS, the growth and performance system, a month into his tenure.
- First phase: "stabilize, de-lever, launch, and continuous improvement"; Investor Day postponed until the company builds a high "say-do ratio".
- Biggest frustration: leverage. He cut the dividend to $0.01 to signal focus on getting under 3x; the recent tender "spent $600 million to take down $850 million".
- Capital allocation follows "The Outsiders": internal investment, M&A as an enabler (cultivated tuck-ins), buybacks when opportune; flexibility over a fixed algorithm.
- Portfolio buckets: invest and grow (ambulatory cardiac monitoring with Bardy, Advanced Surgery), sustain (IV solutions), fix; future changes will be "more pruning than anything".
- New CFO John Rogers (from Smith+Nephew, starting October 1) was chosen for turnaround and medtech experience.
- IV solutions have reached a "new baseline" after Hurricane Helene and should return to low-single-digit growth; injectables supply should be better in 2027; Novum LVP relaunch depends on FDA and Canadian regulators.
- Pricing: GPO renewals gave over 100 basis points of benefit in 2025, less in 2026; next GPO effective in 2028. No change seen in U.S. hospital buying behavior.

## Questions about Baxter International Inc.

### What does Baxter International do?

Baxter makes sterile IV solutions, infusion systems, surgical hemostats and sealants, specialty injectables, smart beds, patient monitoring and respiratory devices for hospitals, surgery centers, nursing homes and home patients in over 100 countries.

### What is Baxter's revenue?

FY2025 net sales were $11.24 billion, +6% reported. For FY2026 Baxter guides to reported sales growth of 4% to 5%, after Q3 2026 sales of $2,976 million.

### How many employees does Baxter have?

Approximately 37,500 employees, about 15,100 in the U.S. and 22,400 outside, according to the FY2025 10-K.

### Who leads Baxter?

Andrew Hider has been President and CEO since 2025; John Rogers joined as CFO on October 1, 2026.

### What is Baxter's strategy?

Stabilize the business, reduce net leverage to approximately 3x by end-2026, drive continuous improvement through Baxter GPS and then move into capital allocation, including tuck-in acquisitions.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
